This bill amends the Federal Food, Drug, and Cosmetic Act to add two new prohibited acts. First, it bars introduction into interstate commerce of any product marketed as a dietary supplement that does not meet the statutory definition of a dietary supplement (section 201(ff)).
Second, it bars introduction of dietary supplements that were prepared, packed, or held with the assistance or direction of a person debarred under section 306. The bill then updates the Act’s import exclusion and seizure provisions so those new prohibitions can be enforced at the border and through civil seizure.
Why this matters: by tying nonconforming marketing and debarred-person involvement to existing FD&C enforcement tools, the bill aims to give FDA and Customs stronger levers to keep dangerous products — including products like tianeptine that states and courts have flagged — out of commerce. It also creates new compliance risk for manufacturers, importers, and supply-chain service providers because handling or marketing choices may trigger federal exclusion and seizure without new substantive rulemaking.
At a Glance
What It Does
The bill adds two specific prohibited acts to 21 U.S.C. 331: (jjj) introducing into interstate commerce products marketed as dietary supplements that fail the statutory definition; and (kkk) introducing dietary supplements prepared, packed, or held with the assistance or direction of persons debarred under section 306. It updates import exclusion (21 U.S.C. 381(a)) and seizure authority (21 U.S.C. 334) to reference the new paragraphs.
Who It Affects
Manufacturers, labelers, distributors, and importers of dietary supplements and supplement-like products; third-party packers, contract manufacturers, and logistics providers who may have personnel or contractors that are debarred; and FDA and Customs officials responsible for detention and seizure.
Why It Matters
The changes convert marketing and supply-chain practices into grounds for immediate border exclusion and civil seizure under existing FD&C authorities, lowering the administrative path to remove products from commerce. That shifts enforcement focus from post-market recall to pre-entry exclusion and increases compliance obligations across the supply chain.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds two new “prohibited acts” to the FD&C Act designed to target products that are marketed as dietary supplements but fall outside the statutory definition, and products tied to debarred individuals. The first prohibition references the definition of dietary supplement in section 201(ff) and makes it unlawful to introduce into interstate commerce a product that is marketed as a dietary supplement when it does not meet that definition.
In practice, that targets products that carry the marketing or labeling of a supplement but are functionally adulterants, drugs, or contain controlled or otherwise prohibited substances.
The second prohibition focuses on the supply chain: it bars introducing dietary supplements into interstate commerce if the product was prepared, packed, or held with the assistance or at the direction of a person debarred under section 306 of the FD&C Act. Section 306 debarments typically arise from conviction or serious misconduct related to FDA-regulated activities; this clause extends the consequences of debarment into the supplement marketplace by making downstream products subject to exclusion.To make those prohibitions operational at the border and in courts, the bill amends the import exclusion provision in section 801(a) to allow Customs to refuse entry of items violating the new paragraphs, and it amends the seizure statute in section 304 to list the new paragraphs among the grounds for civil seizure and condemnation.
The text relies on existing FD&C penalties and remedies tied to prohibited acts rather than creating new penalties, so enforcement proceeds through the Act’s current administrative and civil processes.
The Five Things You Need to Know
The bill inserts two new prohibited-act paragraphs into 21 U.S.C. 331: paragraph (jjj) (products marketed as dietary supplements that do not meet section 201(ff)) and paragraph (kkk) (dietary supplements prepared, packed, or held with assistance/direction of a person debarred under section 306).
It amends 21 U.S.C. 381(a) (import refusal) to add the new paragraphs (jjj) and (kkk) among the statutory bases Customs/FDA can use to deny entry of shipments.
It amends 21 U.S.C. 334 (seizure) to classify products violating the new paragraphs as subject to civil seizure and condemnation under existing seizure procedures.
The bill ties enforcement to the statutory definition at section 201(ff) rather than adding a new ingredient list or explicit bans — meaning disputes about whether a product 'meets the definition' will be pivotal.
The provision on debarred persons makes supply-chain involvement by a debarred individual or entity a standalone ground for exclusion, even if the finished product otherwise appears to be a lawful dietary supplement.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short title: the 'Prohibiting Tianeptine and Other Dangerous Products Act of 2026.' The title signals legislative intent focused on particular risky substances and supplement-like products, which frames enforcement priorities even though the operative text uses the statutory dietary supplement definition rather than naming specific chemicals.
Creates two new prohibited acts
Paragraph (jjj) makes it unlawful to introduce into interstate commerce any product marketed as a dietary supplement that does not meet the statutory definition in 201(ff). Paragraph (kkk) prohibits introduction of a dietary supplement prepared, packed, or held with the assistance or at the direction of a person debarred under section 306. Practically, (jjj) targets marketing/labeling strategies that attempt to classify a product as a supplement to evade drug regulation; (kkk) extends debarment consequences down the chain to finished goods, making involvement by debarred actors a standalone compliance trigger.
Adds new grounds for import refusal
The bill updates the import exclusion clause so Customs and FDA can refuse entry of articles that violate paragraphs (jjj) or (kkk). That narrows the administrative gap between identifying a problematic product and preventing its physical entry: rather than relying solely on post-entry recall or detention, officials can act at the border under established import detention and refusal processes.
Allows civil seizure and condemnation for products violating the new prohibitions
The bill adds the new prohibited-act paragraphs to the list of statutory violations that support civil seizure and condemnation. This means prosecutors and FDA can seek judicial seizure remedies under existing procedures when a product is in commerce, not just at the border. The amendment leverages current civil enforcement tools rather than creating a new civil penalty regime.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers concerned about dangerous supplement-like products — they gain a clearer statutory route for FDA/Customs to exclude or seize products marketed as supplements but containing unsafe or noncompliant substances.
- FDA and Customs (CBP) enforcement teams — they receive explicit statutory grounds to detain, exclude, and seize products tied to nonconforming marketing or debarred personnel, reducing reliance on case-by-case legal theories.
- Hospitals and emergency responders — by targeting entry and distribution channels for risky products (e.g., certain psychoactive compounds), the bill could reduce downstream poisoning and overdose incidents that burden healthcare systems.
Who Bears the Cost
- Supplement manufacturers and labelers — they must reassess product formulations, labeling, and marketing claims to ensure alignment with section 201(ff), and face higher risk of exclusion or seizure if lines are blurred.
- Importers, brokers, and logistics providers — they face increased border scrutiny and potential cargo refusals; those who use third-party packers must screen suppliers for debarment exposure.
- Contract manufacturers and packers — firms that work with debarred individuals, even as subcontractors, could create exclusion risk for downstream clients, which may force stricter vetting and contract changes (and associated costs).
Key Issues
The Core Tension
The bill balances two legitimate goals — protecting the public from dangerous, supplement-marketed products and preserving access to lawful dietary supplements — by using a blunt enforcement lever (import exclusion and seizure) tied to marketing and supply-chain involvement; the core dilemma is that using broad, administrable tools to block unsafe products risks ensnaring borderline or legitimate products and adding compliance burdens that may chill lawful commerce without clearer substantive criteria.
The bill relies heavily on the statutory definition in section 201(ff) to distinguish lawful dietary supplements from products that should be regulated as drugs, adulterated foods, or otherwise. That makes the line-drawing between marketing, label claims, formulation, and intended use central to enforcement.
Expect litigation and inter-agency disputes over what it means to 'market' a product as a dietary supplement when marketing language, distribution channels, or implied claims are ambiguous. The statute does not add a new ingredient ban or list; instead, it converts nonconforming marketing into a ground for exclusion, which shifts the battleground to interpretation rather than substance.
The debarment-based prohibition raises practical and legal questions. Section 306 debarments are individualized actions with procedural protections; extending debarment consequences to goods handled 'with the assistance of, or at the direction of' a debarred person will require factual showings about the nature and materiality of that assistance.
Small firms that engage contractors or temporary workers may face disproportionate risk if a single debarred individual was involved in a limited way. Finally, the bill expands operational demands on Customs and FDA — more hold-and-refuse decisions and seizure actions without accompanying appropriations could strain resources and slow legitimate trade, and the statute does not create new administrative procedures to streamline case handling.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.